{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T03:37:50Z","timestamp":1793417870830,"version":"4.5.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T00:00:00Z","timestamp":1597190400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T00:00:00Z","timestamp":1597190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s10147-020-01763-1","type":"journal-article","created":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T11:03:07Z","timestamp":1597230187000},"page":"2075-2082","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Oxaliplatin-induced increase in splenic volume: experiences from multicenter study in Japan"],"prefix":"10.1007","volume":"25","author":[{"given":"Ryo","family":"Ohta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1436-7482","authenticated-orcid":false,"given":"Takeshi","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuma","family":"Iwai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohji","family":"Tanakaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichiro","family":"Ishibashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Yoshimatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chihiro","family":"Kosugi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Tsubaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoshi","family":"Oya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiji","family":"Koda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyuki","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,12]]},"reference":[{"key":"1763_CR1","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1097\/00000658-199909000-00004","volume":"230","author":"Y Fong","year":"1999","unstructured":"Fong Y, Fortner J, Sun RL et al (1999) Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 230:309\u2013318","journal-title":"Ann Surg"},{"key":"1763_CR2","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1016\/S1470-2045(14)70486-3","volume":"15","author":"HJ Schmoll","year":"2014","unstructured":"Schmoll HJ, Twelves C, Sun W et al (2014) Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials. Lancet Oncol 15:1481\u20131492","journal-title":"Lancet Oncol"},{"key":"1763_CR3","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1093\/annonc\/mdh095","volume":"15","author":"L Rubbia-Brandt","year":"2004","unstructured":"Rubbia-Brandt L, Audard V, Sartoretti P et al (2004) Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 15:460\u2013466","journal-title":"Ann Oncol"},{"key":"1763_CR4","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1200\/JCO.2009.27.5701","volume":"28","author":"MJ Overman","year":"2010","unstructured":"Overman MJ, Maru DM, Charnsangavej C et al (2010) Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury. J Clin Oncol 28:2549\u20132555","journal-title":"J Clin Oncol"},{"key":"1763_CR5","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/S0140-6736(08)60455-9","volume":"371","author":"B Nordlinger","year":"2008","unstructured":"Nordlinger B, Sorbye H, Glimelius B et al (2008) Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 371:1007\u20131016","journal-title":"Lancet"},{"key":"1763_CR6","doi-asserted-by":"publisher","first-page":"4983","DOI":"10.1200\/JCO.2006.05.8156","volume":"24","author":"T Aloia","year":"2006","unstructured":"Aloia T, Sebagh M, Plasse M et al (2006) Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol 24:4983\u20134990","journal-title":"J Clin Oncol"},{"key":"1763_CR7","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1097\/SLA.0b013e31815774de","volume":"247","author":"H Nakano","year":"2008","unstructured":"Nakano H, Oussoultzoglou E, Rosso E et al (2008) Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg 247:118\u2013124","journal-title":"Ann Surg"},{"key":"1763_CR8","doi-asserted-by":"publisher","first-page":"4304","DOI":"10.1200\/JCO.2008.16.1893","volume":"26","author":"J Ward","year":"2008","unstructured":"Ward J, Guthrie JA, Sheridan MB et al (2008) Sinusoidal obstructive syndrome diagnosed with superparamagnetic iron oxide-enhanced magnetic resonance imaging in patients with chemotherapy-treated colorectal liver metastases. J Clin Oncol 26:4304\u20134310","journal-title":"J Clin Oncol"},{"key":"1763_CR9","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/j.ejso.2009.01.015","volume":"35","author":"TR O\u2019Rourke","year":"2009","unstructured":"O\u2019Rourke TR, Welsh FKS, Tekkis PP et al (2009) Accuracy of liver-specific magnetic resonance imaging as a predictor of chemotherapy-associated hepatic cellular injury prior to liver resection. Eur J Surg Oncol 35:1085\u20131091","journal-title":"Eur J Surg Oncol"},{"key":"1763_CR10","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.ejso.2013.12.009","volume":"40","author":"K Imai","year":"2014","unstructured":"Imai K, Emi Y, Beppu T et al (2014) Splenic volume may be a useful indicator of the protective effect of bevacizumab against oxaliplatin-induced hepatic sinusoidal obstruction syndrome. Eur J Surg Oncol 40:559\u2013566","journal-title":"Eur J Surg Oncol"},{"key":"1763_CR11","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1002\/jso.24756","volume":"116","author":"T Iwai","year":"2017","unstructured":"Iwai T, Yamada T, Koizumi M et al (2017) Oxaliplatin-induced increase in splenic volume; irreversible change after adjuvant FOLFOX. J Surg Oncol 116:947\u2013953","journal-title":"J Surg Oncol"},{"key":"1763_CR12","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s00384-018-2979-9","volume":"33","author":"C Kosugi","year":"2018","unstructured":"Kosugi C, Koda K, Ishibashi K et al (2018) Safety of mFOLFOX6\/XELOX as adjuvant chemotherapy after curative resection of stage III colon cancer: phase II clinical study (The FACOS study). Int J Colorectal Dis 33:809\u2013817","journal-title":"Int J Colorectal Dis"},{"key":"1763_CR13","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1007\/s00595-019-1771-y","volume":"49","author":"K Yoshimatsu","year":"2019","unstructured":"Yoshimatsu K, Ishibashi K, Koda K et al (2019) A Japanese multicenter phase II study of adjuvant chemotherapy with mFOLFOX6\/CAPOX for stage III colon cancer treatment after D2\/D3 lymphadenectomy. Surg Today 49:498\u2013506","journal-title":"Surg Today"},{"key":"1763_CR14","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1159\/000210025","volume":"76","author":"R Angitapalli","year":"2009","unstructured":"Angitapalli R, Litwin AM, Kumar PRG et al (2009) Adjuvant FOLFOX chemotherapy and splenomegaly in patients with stages II-III colorectal cancer. Oncology 76:363\u2013368","journal-title":"Oncology"},{"key":"1763_CR15","first-page":"3357","volume":"32","author":"EJ Jung","year":"2012","unstructured":"Jung EJ, Ryu CG, Kim G et al (2012) Splenomegaly during oxaliplatin-based chemotherapy for colorectal carcinoma. Anticancer Res 32:3357\u20133362","journal-title":"Anticancer Res"},{"key":"1763_CR16","doi-asserted-by":"publisher","first-page":"653","DOI":"10.2147\/TCRM.S150968","volume":"14","author":"A El Chediak","year":"2018","unstructured":"El Chediak A, Haydar AA, Hakim A et al (2018) Increase in spleen volume as a predictor of oxaliplatin toxicity. Ther Clin Risk Manag 14:653\u2013657","journal-title":"Ther Clin Risk Manag"},{"key":"1763_CR17","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1111\/j.1365-2559.2012.04208.x","volume":"61","author":"CP Vreuls","year":"2012","unstructured":"Vreuls CP, Van Den Broek MA, Winstanley A et al (2012) Hepatic sinusoidal obstruction syndrome (SOS) reduces the effect of oxaliplatin in colorectal liver metastases. Histopathology 61:314\u2013318","journal-title":"Histopathology"},{"key":"1763_CR18","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1056\/NEJMoa1713709","volume":"378","author":"A Grothey","year":"2018","unstructured":"Grothey A, Sobrero AF, Shields AF et al (2018) Duration of adjuvant chemotherapy for stage III colon cancer. N Engl J Med 378:1177\u20131188","journal-title":"N Engl J Med"},{"key":"1763_CR19","doi-asserted-by":"publisher","first-page":"94","DOI":"10.3109\/07357907.2015.1104689","volume":"34","author":"Y Guo","year":"2016","unstructured":"Guo Y, Xiong BH, Zhang T et al (2016) XELOX vs. FOLFOX in metastatic colorectal cancer: an updated meta-analysis. Cancer Invest 34:94\u2013104","journal-title":"Cancer Invest"},{"key":"1763_CR20","doi-asserted-by":"publisher","first-page":"990","DOI":"10.4143\/crt.2015.296","volume":"48","author":"MJ Kim","year":"2016","unstructured":"Kim MJ, Han SW, Lee DW et al (2016) Splenomegaly and its associations with genetic polymorphisms and treatment outcome in colorectal cancer patients treated with adjuvant FOLFOX. Cancer Res Treat 48:990\u2013997","journal-title":"Cancer Res Treat"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-020-01763-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-020-01763-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-020-01763-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,11]],"date-time":"2021-08-11T23:06:06Z","timestamp":1628723166000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-020-01763-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,12]]},"references-count":20,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1763"],"URL":"https:\/\/doi.org\/10.1007\/s10147-020-01763-1","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,12]]},"assertion":[{"value":"22 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Keiichiro Ishibashi received research grant from Yakult Co., Ltd. and Chugai Pharmaceutical Co., Ltd. Masatoshi Oya received research grant from Yakult Co., Ltd. Hideyuki Ishida received research grant from Yakult Co., Ltd. and Chugai Pharmaceutical Co., Ltd. Other authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}